TY - JOUR
T1 - IDH2 mutations in acute myeloid leukemia
AU - Babakhanlou, Rodrick
AU - DiNardo, Courtney
AU - Borthakur, Gautam
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Advances in the treatment of acute myeloid leukemia (AML) over the last 40 years have been limited. With an improved understanding of the pathophysiology of the disease, the advent of new treatment options has enriched the armamentarium of the physician to combat the disease. Mutations of the isocitrate dehydrogenase (IDHs) genes are common in AML and occur in 20-30% of cases. These mutations lead to DNA hypermethylation, aberrant gene expression, cell proliferation, and abnormal differentiation. Targeting mutant IDH, either as monotherapy or in combination with hypomethylating agents (HMAs) or BCL-2 inhibitors, has opened new avenues of therapy for these patients. This review will outline the function of IDHs and focus on the biological effects of IDH2 mutations in AML, their prognosis and treatment options.
AB - Advances in the treatment of acute myeloid leukemia (AML) over the last 40 years have been limited. With an improved understanding of the pathophysiology of the disease, the advent of new treatment options has enriched the armamentarium of the physician to combat the disease. Mutations of the isocitrate dehydrogenase (IDHs) genes are common in AML and occur in 20-30% of cases. These mutations lead to DNA hypermethylation, aberrant gene expression, cell proliferation, and abnormal differentiation. Targeting mutant IDH, either as monotherapy or in combination with hypomethylating agents (HMAs) or BCL-2 inhibitors, has opened new avenues of therapy for these patients. This review will outline the function of IDHs and focus on the biological effects of IDH2 mutations in AML, their prognosis and treatment options.
KW - Acute myeloid leukemia
KW - AML
KW - enasidenib
KW - IDH2 inhibitors
KW - IDH2 mutations
UR - http://www.scopus.com/inward/record.url?scp=85165382529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165382529&partnerID=8YFLogxK
U2 - 10.1080/10428194.2023.2237153
DO - 10.1080/10428194.2023.2237153
M3 - Review article
C2 - 37462435
AN - SCOPUS:85165382529
SN - 1042-8194
VL - 64
SP - 1733
EP - 1741
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -